GGrantIndex
Sort

15,273 grants matching antimicrobial resistance

O-polysaccharide (OPS)-IpaB Conjugate Vaccine to Prevent Shigellosis

$910,903
Marcela F Pasetti · University Of Maryland Baltimore · R01 · FY2025 · AI

Rapid detection of pathogens and antimicrobial susceptibility directly in patient samples

$910,291
Sadanand Gite · First Light Diagnostics , Inc. · R01 · FY2016 · AI

Lead optimization of a novel cyclic aryl-indole efflux pump inhibitor (EPI) series in combination with levofloxacin against Pseudomonas aeruginosa

$910,179
Ajit K Parhi · Taxis Pharmaceuticals, Inc. · R44 · FY2024 · AI

Ultrarapid culture-independent detection of high-priority carbepenem resistant Enterobacteriaceae directly from blood

$909,109
Connie Savor Price · Denver Health And Hospital Authority · R01 · FY2018 · AI

Novel pre-coital, non-hormonal multipurpose prevention technology (MPT)

$908,910
Pavimol Angsantikul · Population Council · R01 · FY2023 · AI

Defining immunological mechanisms of serovar cross-reactivity to develop broad spectrum protective vaccines for typhoidal and non-typhoidal Salmonella infections in humans

$906,651
Marcelo B. Sztein · University Of Maryland Baltimore · U19 · FY2023 · AI

New Tricks for 'Old' Drugs: PK/PD of Polymyxin Nonantibiotic Combinations

$905,775
Jian Li · Monash University · R01 · FY2014 · AI

SBIR Phase II: New Antimicrobial Technologies to Eliminate Salmonella Carriage in Poultry

$905,622
Kathryn Geldart · General Probiotics Inc · · FY2017 · TIP

RECENT OUTBREAKS OF FOODBORNE DISEASE ASSOCIATED WITH LOW WATER ACTIVITY (DRY) PRODUCTS HAVE INCLUDED CEREAL, FLOUR, PEANUT BUTTER, CHOCOLATE, PET FOOD, INFANT FORMULA, AND SPICES. THESE INCIDENTS HAVE RESULTED IN SIGNIFICANT MORBIDITY AND MORTALITY, AS WELL AS ECONOMIC CONSEQUENCES FOR THE FOOD INDUSTRY. OUTBREAKS DUE TO MICROBIAL PATHOGEN CONTAMINATION, UNDECLARED ALLERGENS, AND INCIDENTS OF COMMERCIAL SPOILAGE INCREASE FOOD WASTE, DECREASE CONSUMER SATISFACTION, AND THREATEN PUBLIC HEALTH. HOWEVER, BECAUSE OF THE DIFFICULTY IN ELIMINATING THESE HAZARDS IN DRY PRODUCTS ONCE CONTAMINATED, PREVENTING CONTAMINATION FROM OCCURRING IN THE FIRST PLACE IS ESSENTIAL. THE PRIMARY MEANS OF PREVENTING CROSS-CONTAMINATION IS THROUGH SANITATION IN THE FOOD PRODUCTION ENVIRONMENT, BUT DRY FOOD MANUFACTURING POSES ADDITIONAL CHALLENGES AS WATER MUST OFTEN BE EXCLUDED. SUBSEQUENTLY, SANITATION STRATEGIES THAT ENHANCE REMOVAL OF FOOD SOILS AND ALLERGENIC RESIDUES, AND INACTIVATE MICROBIAL PATHOGENIC AND SPOILAGE TARGETS, WITHOUT THE INTRODUCTION OF MOISTURE, REPRESENT AN AREA OF NEED AND OPPORTUNITY FOR FOOD MANUFACTURERS. THIS RESEARCH WILL ADDRESS THE ABOVE CHALLENGE AREA THROUGH THE DEVELOPMENT OF NOVEL MANUFACTURING TECHNOLOGIES VALIDATED AGAINST RELEVANT MICROBIAL AND FOOD SOIL TARGETS UNDER CONTROLLED AND REAL-WORLD CONDITIONS. THE FIRST OF THESE TECHNOLOGIES TO BE EVALUATED IS AIR IMPINGEMENT.THIS WILL BE DELIVERED AS A MOVEABLE AIRSTREAM TO DISLODGE SOIL PARTICLES OF VARIOUS FOOD TYPES. AIR AT VELOCITIES AS HIGH AS 30 M/S WILL BE DIRECTED AT A SURFACE TO CREATE UNIQUE FLOW CHARACTERISTICS AT THE INTERFACE BETWEEN THE AIR AND THE SURFACE. IN ADDITION TO ENHANCEMENT OF HEAT AND MASS TRANSFER, THE FLOW CHARACTERISTICS WOULD BE EXPECTED TO ENHANCE MOMENTUM TRANSFER AT THE SURFACE AND REMOVE VERY SMALL PARTICLES (INCLUDING MICROBIAL CELLS) FROM THE SURFACE. THE SECOND OF THESE TECHNOLOGIES TO BE APPLIED IS SUPERCRITICAL STEAM WHICH, DESPITE ITS NAME, DOES NOT RESULT IN MOISTURE CONDENSING ON PRODUCTION SURFACES. RATHER, THE HIGH TEMPERATURES APPLIED WILL SERVE TO KILL PATHOGENIC BACTERIA AND SPOILAGE FUNGI THAT REMAIN ON PRODUCT CONTACT AND ADJACENT SURFACES. DURING TREATMENT, THE STEAM IS HEATED TO A TEMPERATURE HIGHER THAN BOILING POINT CORRESPONDING TO ITS PRESSURE. BY INCREASING THE TEMPERATURE ABOVE ITS BOILING POINT, THE SUPER-HEATED STEAM CONTAINS ABOUT 5% MOISTURE AND HAS PROPERTIES SIMILAR TO HOT GAS. WHEN SUPERHEATED STEAM CONTACTS MATERIAL, ITS SENSIBLE HEAT IS USED TO HEAT THE SURFACE. THERMAL ENERGY FROM THE SUPERHEATED STEAM CONTRIBUTES TO THE INACTIVATION OF MICROBES. IT DENATURES THE PROTEINS AND ENZYMES AND KILLS THE BACTERIA WITHOUT THE ACQUISITION OF ANY POTENTIAL CHEMICAL RESISTANCE OR CHEMICAL RESIDUE LEFT BEHIND. SINCE SUPERHEATED STEAM ACTS AS A GAS, IT IS ABLE TO DIFFUSE AND PENETRATE BACTERIAL BIOFILM MORE EFFECTIVELY THAN ANTIMICROBIAL LIQUID SOLUTIONS.BENCHTOP AND PILOT SCALE VERSIONS OF THESE TECHNOLOGIES WILL BE FABRICATED AND TESTED AGAINST A PANEL OF "WORST-CASE-SCENARIO" FOOD AND ALLERGENIC SOILS AS WELL AS MICROBIAL PATHOGENS, SPOILAGE ORGANISMS, AND THEIR SURROGATES. RELEVANT MICROBIAL TARGETS INCLUDE SALMONELLA, E. COLI, AND SPOILAGE FUNGI. THESE WILL BE ASSESSED FOR THEIR RESISTANCE TO THE TREATMENTS AS WELL AS THEIR ABILITY TO ADHERE TO SURFACES AND RESIST REMOVAL. ADHERENCE WILL ALSO BE EVALUATED AMONG FOOD SOILS THAT INCLUDE HIGH FAT SEMISOLIDS, PROTEIN POWDERS, AND SUGAR SYRUPS. ALLERGENIC RESIDUES FOR NUTS, WHEAT, AND DIARY WILL ALSO BE CONSIDERED AS A TARGET OF SANITATION PROGRAMS. THE EFFICACY OF THE NOVEL MANUFACTURING TECHNOLOGIES DEVELOPED HEREIN WILL BE EVALUATED USING A VARIETY OF MICROBIOLOGICAL, BIOCHEMICAL, AND IMAGING TECHNOLOGIES. THESE RESULTS WILL BE COMPARED TO THE EFFICACY OF CONVENTIONAL SCRAPING, VACUUMING, AND BRUSHING METHODS COMMONLY APPLIED. COLLECTIVELY, THIS WORK WILL HELP ESTABLISH BEST PRACTICES AND VERIFICATION METHODS FOR SANITATION IN DRY FOOD PROCESSING ENVIRONMENTS.THE NOVEL MANUFACTURING TECHNOLOGIES DEVELOPED HEREIN ARE POTENTIAL ALTERNATIVES TO EXISTING METHODS THAT CAN ENHANCE MANUFACTURER CONTROL OVER ENVIRONMENTAL SANITATION. THIS WILL, IN TURN, IMPROVE SAFETY THROUGH THE UTILIZATION OF PRACTICES WHICH REDUCE THE DEMAND ON WATER, SANITIZERS,AND WASTE STREAM MANAGEMENT IN FOOD MANUFACTURING, ALIGNING ALSO WITH CONSUMER PREFERENCES AND SUSTAINABILITY GOALS.

$905,233
Cornell University · · FY2020 · National Institute of Food and Agriculture

A systems analysis of drug tolerance in Mycobacterium tuberculosis

$904,421
Nitin S Baliga · Institute For Systems Biology · R01 · FY2022 · AI

Development of Vaccines to Prevent Tuberculosis

$903,787
Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI

Obstetric Pharmacology Research Units Network Center at UTMB-Galveston

$903,786
Gary D Hankins · University Of Texas Med Br Galveston · U10 · FY2013 · HD

Discovery of Molecules to disrupt the outer membrane of Gram-negative pathogens

$903,133
Daniel E Kahne · Harvard Medical School · U19 · FY2016 · AI

A Resource for Biomedical Mass Spectrometry

$901,678
Michael L Gross · Washington University · P41 · FY2011 · RR

Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent

$901,490
Radhakrishnan P Iyer · Spring Bank Technologies, Inc. · R01 · FY2015 · AI

Targeted Clinical Trials to Reduce the Risk of Antimicrobial Resistance

$901,465
Alehandro Hoberman · University Of Pittsburgh At Pittsburgh · N01 · FY2012 · AI

Anti-Virulence FimH Inhibitors for the Treatment and Prevention of UTIs

$901,235
Thomas Joseph Hannan · Fimbrion Therapeutics, Inc. · R44 · FY2017 · AI

Endolysins as tools to eradicate pneumococcal biofilms and development of protective immunity

$901,010
Norberto Gonzalez-Juarbe · J. Craig Venter Institute, Inc. · R01 · FY2023 · AI

Activate Silent and Cryptic Intact Fungal SM Gene Clusters through FACs for Novel Antibiotics Discovery

$900,553
Chengcang Charles Wu · Intact Genomics, Inc. · R44 · FY2016 · AI

A systems approach to manipulate microbial adaptation to structured environments

$900,470
Nitin S Baliga · Institute For Systems Biology · R01 · FY2020 · AI

** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** INTEGRATION OF DATA FROM THE HUMAN, ANIMAL, AND ENVIRONMENTAL SECTORS IS CRITICAL TO IMPLEMENTING A ONE-HEALTH APPROACH TO ADDRESS ANTIMICROBIAL RESISTANCE (AMR). THIS PROPOSAL AIMS TO IMPROVE THE UNDERSTANDING OF THE ENVIRONMENTAL COMPONENT OF THE ONE-HEALTH APPROACH IN ADDRESSING AMR BY TARGETING THREE ISSUES: (1) LIMITED DATA IN SHOWING THE CONNECTION OF AMR BACTERIA FOUND IN THE ENVIRONMENT TO THOSE COLONIZING AND INFECTING HUMANS AND ANIMALS; (2) LIMITED OVERLAP IN THE GENOMES OF AMR PATHOGENS IN HUMANS AND IN ANIMALS, LEAVING DOUBT OVER THE SIGNIFICANCE OF AMR TRANSMISSION BETWEEN HUMANS AND ANIMALS, DIRECTLY OR INDIRECTLY THROUGH THE ENVIRONMENT; (3) NEED FOR ENGAGEMENT FROM THE PUBLIC AND STAKEHOLDERS IN UNDERSTANDING THE ROLE OF THE ENVIRONMENT IN DISSEMINATING AND MITIGATING AMR BETWEEN HUMANS AND ANIMALS. OUR OVERALL OBJECTIVE IS TO DEVELOP STRATEGIES TO DECIPHER HOW THE ENVIRONMENT MAY CONTRIBUTE TO THE TRANSMISSION AND EVOLUTION OF AMR BACTERIA AND GENES RELEVANT TO HUMAN AND ANIMAL HEALTH. THREE OBJECTIVES INCLUDE: (1) TRACK THE TRANSMISSION OF CLINICALLY RELEVANT AMR BACTERIA AND GENES OF HUMAN- AND ANIMAL-ORIGIN IN THE ENVIRONMENT; (2) INVESTIGATE THE EVOLUTION OF AMR IN FECAL BACTERIA IN THE ENVIRONMENT BY ASSESSING THE ACQUISITION OF AMR GENES FROM ENVIRONMENTAL MICROBIOTA; (3) IMPROVE KNOWLEDGE OF AMR-RELATED RISKS AND INSPIRE THE ADOPTION OF PRACTICES AMONG FOOD PRODUCERS AND CONSUMERS TO COMBAT AMR-RELATED HEALTH AND FOOD SAFETY RISKS ACROSS THE FOOD CHAIN. TO ACHIEVE THE OBJECTIVES, A TEAM IS ASSEMBLED WITH EXPERTISE IN HUMAN MEDICINE, VETERINARY DIAGNOSTICS, ENVIRONMENTAL MICROBIOLOGY, ANIMAL SCIENCE, AND EXTENSION AND EDUCATION.

$900,000
Board Of Regents Of The University Of Nebraska · · FY2024 · National Institute of Food and Agriculture

Host defense-stimulating macrocyclic peptides for treatment of MDR bacterial infections

$899,573
Michael E Selsted · University Of Southern California · R01 · FY2020 · AI

Novel broad spectrum therapeutic glycans against Category B pathogens

$899,251
David S Newburg · Boston College · U01 · FY2010 · AI

PrEP and dPEP: Doxycycline post-exposure prophylaxis for prevention of sexually transmitted infections among Kenyan women using HIV pre-exposure prophylaxis

$898,475
Jared Baeten · University Of Washington · R01 · FY2023 · AI

NGS based metagenomic screening of ocular infections

$898,365
Espoir Kyubwa · Chromologic, Llc · R42 · FY2025 · EY